A substance-use-disorder treatment denial can feel brutally technical at exactly the wrong time. Families are trying to keep care in place, clinicians are documenting risk and progress, and the insurance company is often using a short phrase like “not medically necessary,” “wrong level of care,” or “not covered under the plan.” In many cases, the real fight is not just about one sentence in a denial letter. It is about three separate things happening at once: what the plan says, what the clinical record shows, and whether the insurer is treating substance-use-disorder care more restrictively than medical or surgical care.
That three-part framework is where many appeals become stronger and more organized.
In this post you’ll learn how to use plan language, clinical evidence, and parity arguments together in a substance-use-disorder appeal, especially when the denial involves residential treatment, partial hospitalization, intensive outpatient care, or ongoing authorization disputes. If you want a broader overview of how these denials usually work, this guide on why behavioral-health coverage fights happen in the first place gives helpful background before diving into the appeal itself.
<aside> 💡 Scroll to the bottom for every post in this series.
</aside>
Insurers often frame a denial as a pure medical-necessity issue. But in practice, many substance-use-disorder appeals involve a combination of questions:
That last question is where the federal Mental Health Parity and Addiction Equity Act (MHPAEA) often matters. CMS explains that if a plan offers mental health or substance-use-disorder benefits, it generally cannot impose nonquantitative treatment limitations, such as prior authorization or medical-management rules, unless the processes and evidentiary standards are comparable to — and applied no more stringently than — those used for medical/surgical benefits in the same classification. The 2024 final rules also reinforced that parity applies to standards affecting scope or duration of services, including things like medical management, facility-type limits, and network-related restrictions (CMS).
That is a big deal in residential and intensive outpatient disputes. A denial may look clinical on the surface, but the appeal may reveal a broader issue: the plan may be using more restrictive review practices for addiction treatment than for analogous medical care.
Before writing the appeal itself, it often helps to gather the governing documents and compare them side by side.
In many cases, the core packet includes: